- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/60 - N-oxides
Patent holdings for IPC class C07D 215/60
Total number of patents in this class: 49
10-year publication summary
|
8
|
8
|
1
|
3
|
1
|
2
|
3
|
2
|
3
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Zydus Lifesciences Limited | 106 |
7 |
| BIAL - Portela & CA, S.A. | 239 |
4 |
| Astellas Pharma Inc. | 1112 |
2 |
| Cadila Healthcare Limited | 323 |
2 |
| Exelixis, Inc. | 397 |
2 |
| Incyte Corporation | 978 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2849 |
2 |
| Firmenich Incorporated | 139 |
2 |
| Laurel Therapeutics Ltd. | 6 |
2 |
| BASF SE | 20565 |
1 |
| Merck Sharp & Dohme Corp. | 2213 |
1 |
| Janssen Pharmaceutica N.V. | 3589 |
1 |
| Pfizer Inc. | 3385 |
1 |
| Bayer Cropscience AG | 2125 |
1 |
| Bayer Schering Pharma AG | 423 |
1 |
| Bayer Pharma AG | 1086 |
1 |
| Board of Regents, The University of Texas System | 5671 |
1 |
| Vertex Pharmaceuticals Incorporated | 1584 |
1 |
| Korea Advanced Institute of Science and Technology | 4230 |
1 |
| University of South Florida | 1836 |
1 |
| Other owners | 13 |